NMD4C Hiring a Postdoc to Develop Spinal Muscular Atrophy Decision Aid
We are looking to fill a postdoctoral position to develop a tool to support decisions of families and clinicians in selecting a treatment plan for individuals affected by SMA.
This fellowship is based at the University of British Columbia (UBC) in collaboration with Muscular Dystrophy Canada (MDC) and the NMD4C in a well established and dynamic environment fosters professional development and interdisciplinary research collaborations.
With the support of the research team, the postdoctoral fellow will:
- Acquire training on the Ottawa Decision Aid Framework
- Conduct a decision need assessment among SMA leading clinicians and families
- Develop a tool aid
- Write a grant proposal for implementation and assessment of the SMA tool to CIHR
For further information please read the full job posting.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.